Mark Feinberg, MD, PhD, is president and CEO of IAVI where he leads a global team working to advance the development of vaccines and other biomedical innovations to protect against infection with HIV, tuberculosis, emerging viruses and other public health threats that disproportionately impact people living in low-income countries.
Prior to joining IAVI in 2015, Mark served as chief public health and science officer with Merck Vaccines. In this role, he helped advance the development and global availability of vaccines against rotavirus, human papillomavirus, and other infectious diseases. He also led a range of research initiatives to address unmet health needs in low-income countries including the coordination of a private-public partnership to expedite the development of an efficacious Ebola Zaire vaccine. Following the 2014-2016 Ebola outbreak in West Africa, Mark also played a central role in the establishment of the Coalition for Epidemic Preparedness Innovations (CEPI) and was the inaugural Chair of the CEPI Scientific Advisory Board. Previously, Mark spent more than 20 years exploring HIV/AIDS pathogenesis, treatment, and prevention research and the biology of emerging diseases in both academia and government.
Mark holds an MD and a PhD from Stanford University, and B.A. degree from the University of Pennsylvania. He pursued post-graduate medical training in internal medicine at the Brigham and Women’s Hospital and postdoctoral fellowship training in the laboratory of Dr. David Baltimore at the Whitehead Institute. He has previously served as a faculty member at the University of California, San Francisco and the Emory University School of Medicine, as a medical officer in the Office of AIDS Research at the National Institutes of Health (NIH) and as a fellow in the Advanced Leadership Initiative at Harvard University. Mark is a Fellow of the American College of Physicians, and a member of the Council on Foreign Relations and the Association of American Physicians.
Learning Objectives:
- Identify lessons from the successful development of the Ebola vaccine ERVEBO® that may inform future vaccine development for outbreak-prone diseases affecting low- and middle-income countries
- Gain insights into ongoing efforts to expedite the development of a vaccine against Bundibugyo virus to address the current outbreak in the Democratic Republic of the Congo
- Understand the biologic and programmatic considerations for the development of vaccines targeting outbreak associated pathogens (e.g. filoviruses)
- Discuss how global partnerships, clinical trial design, manufacturing readiness, and regulatory strategy can accelerate vaccine availability for populations at greatest risk
- Understand considerations related to developing public health innovations when there is no commercial incentive
Speaker:
- Mark Feinberg, MD, PhD
This seminar focuses on general pediatrics and was delivered as a Pediatric Grand Rounds Lecture at Children’s Hospital of Philadelphia, on September 16, 2026.
Content Disclaimer
The Terms of Use and Privacy Policy set forth on the website of The Children’s Hospital of Philadelphia apply to any and all uses of and access to this site and the content found here.
The work presented in the presentations, videos, and other content on this site (“Presentations”) includes publicly available medical evidence, a consensus of medical practitioners, and/or opinions of individual practitioners that may differ from consensus opinions. These Presentations are intended only to provide general information and need to be adapted for each specific patient based on the practitioner’s professional judgment, consideration of any unique circumstances, the needs of each patient and their family, the availability of various resources at the health care institution where the patient is located, and other factors. The Presentations are not intended to constitute medical advice or treatment, nor should they be relied upon as such. The Presentations are not intended to create a doctor-patient relationship between/among The Children’s Hospital of Philadelphia, its physicians and the individual patients in question. The information contained in these Presentations are general in nature, and do not and are not intended to refer to specific patients.
CHOP, The Children’s Hospital of Philadelphia Foundation and its or their affiliates, the authors, presenters, practitioners, editors, and others associated with the creation of the Presentations (“CHOP”) are not responsible for errors or omissions in the Presentations; for any outcomes a patient might experience where a clinician reviewed one or more such Presentations in connection with providing care for that patient; and/or for any and all third party content on the site or in the Presentations. CHOP makes no warranty, expressed or implied, with respect to the currency, completeness, applicability or accuracy of the Presentations. Application of the information in or to a particular situation remains the professional responsibility of the practitioner who is directly treating the patient.
To the extent that the Presentations include information regarding drug dosing, in view of ongoing research, changes in government regulations and the constant flow of information relating to drug therapy and drug reactions, the viewer should not rely on the Presentation content, but rather is urged to check the package insert for each drug for indications, dosage, warnings and precautions.
Some drugs and medical devices presented in the Presentations have United States Food and Drug Administration (FDA) clearance for limited use in restricted research settings. It is the responsibility of the practitioner to ascertain the FDA status of each drug or device planned for use in their clinical practice.
You shall indemnify, defend and hold harmless CHOP, The Children’s Hospital of Philadelphia Foundation, and its/their current and former employees, officers, and agents, trustees, and their respective successors, heirs and assigns (“Indemnitees”) against any claims, liability, damage, loss or expenses (including attorneys’ fees and expenses of litigation) in connection with any claims, suits, actions, demands or judgments arising directly or indirectly out of your reference to or use of the Presentations.
The Presentations are protected by copyright laws and in some cases patent laws, and all rights are reserved under such laws. No part of the Presentations may be reproduced in any form by any means, or utilized in any other way, absent prior written permission from the copyright owner.
By starting this module, you agree to our Content Disclaimer and Terms of Service.
Course Includes
- 1 Lesson
- Course Certificate